Lansoprazol Aurovitas Spain

Lansoprazole, the active ingredient in Lansoprazol Aurovitas Spain, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid secretion and is indicated for gastro‑esophageal reflux disease, erosive esophagitis, peptic ulcer disease and Helicobacter pylori eradication regimens. GNH USA supplies Lansoprazol Aurovitas Spain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to reduce gastric acid production in several acid‑related conditions.

- Gastro‑esophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by decreasing acid exposure. - Erosive esophagitis: promotes healing of acid‑induced esophageal lesions. - Peptic ulcer disease: supports ulcer healing and prevents recurrence. - Helicobacter pylori eradication: used as part of combination therapy to improve eradication rates.

Lansoprazole may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild headache reported in some patients. - Diarrhea: loose stools occurring during treatment. - Nausea: feeling of sickness or upset stomach. - Abdominal pain: discomfort or cramping in the abdomen.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Clostridioides difficile infection: severe colitis associated with antibiotic use. - Low magnesium levels: hypomagnesemia leading to muscle cramps or arrhythmia. - Bone fractures: increased risk of hip, wrist, or spine fractures with long‑term use.

When prescribing or dispensing lansoprazole, several precautions should be observed to ensure safe use.

- Assess renal function: dose adjustment may be needed in severe renal impairment. - Review concomitant medications: consider potential interactions with drugs that require acidic pH for absorption. - Monitor long‑term therapy: evaluate need for continued use beyond 8‑12 weeks to avoid bone density loss. - Use caution in elderly: increased risk of fractures and electrolyte disturbances. - Pregnancy and lactation: weigh benefits against potential risks; consult obstetric guidance. - Store at ambient temperature: keep below 25 °C, protect from moisture, retain in original packaging.

Lansoprazole can affect the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid): - Antiretroviral protease inhibitors (e.g., atazanavir): reduced absorption leading to therapeutic failure. - Clopidogrel: decreased activation, potentially lowering antiplatelet effect. - Warfarin: increased INR, heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum levels, monitor for toxicity. - Methotrexate (high dose): reduced renal clearance, watch for toxicity. - Iron salts: decreased absorption, consider timing separation.